找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Nanoformulations in Human Health; Challenges and Appro Sushama Talegaonkar,Mahendra Rai Book 2020 Springer Nature Switzerland AG 2020 nanot

[復(fù)制鏈接]
樓主: 鳥場
51#
發(fā)表于 2025-3-30 11:47:45 | 只看該作者
Preformulation Challenges: The Concept Behind the Selection, Design and Preparation of Nanoformulati; strategy to improve the low entrapment efficiency and stability, etc. This chapter comprehensively summarizes all these aspects of nanoformulation development and proposes solutions for these challenges. Although a variety of nanoformulations have been described in literature, this chapter is rest
52#
發(fā)表于 2025-3-30 14:46:06 | 只看該作者
53#
發(fā)表于 2025-3-30 19:17:28 | 只看該作者
54#
發(fā)表于 2025-3-30 23:48:23 | 只看該作者
Recent Developments and Challenges in Nanoformulations Targeting Various Ailments of the Colontructure remains integrated due to minimum enzymatic activity..In recent years, the advancement in nanotechnology has tremendously helped target drugs to the colon. The nanoformulations target the drugs to the colon by using simple approaches that may be based on size, pH sensitivity, surface charge
55#
發(fā)表于 2025-3-31 03:53:42 | 只看該作者
56#
發(fā)表于 2025-3-31 07:07:15 | 只看該作者
57#
發(fā)表于 2025-3-31 11:24:35 | 只看該作者
Application of Biocompatible Nanocarriers in Glaucoma: Challenges and Advancesile, dosing frequency, systemic untoward effect, and poor patient compliance. Low drug bioavailability due to transient contact time, rapid washout by tearing, nasolacrimal drainage are some of the major issues related to the ocular pharmacotherapy. To overcome these challenges, novel biocompatible
58#
發(fā)表于 2025-3-31 14:53:01 | 只看該作者
59#
發(fā)表于 2025-3-31 18:14:40 | 只看該作者
60#
發(fā)表于 2025-3-31 23:55:28 | 只看該作者
Nanosized Labile and Particulate Ingredients in Topical Formulations: A Strategic Approach Against Pf the major cosmetic concerns and designing a broad spectrum photoprotective formulation is the need of the hour. Drugs generally used in treating skin ailments fall in the category of anti-allergic and anti-inflammatory agents, antioxidants, anti-infectives, immunosuppressants and anticancer agents
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點評 投稿經(jīng)驗總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機版|小黑屋| 派博傳思國際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-6 03:32
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
灵寿县| 霞浦县| 青州市| 万载县| 新津县| 抚顺市| 门源| 衡山县| 新和县| 白沙| 洛南县| 钦州市| 福安市| 罗城| 交城县| 福海县| 台山市| 滨州市| 馆陶县| 商洛市| 旬阳县| 湘潭县| 泾川县| 密山市| 舟曲县| 墨竹工卡县| 手游| 安阳县| 时尚| 简阳市| 宁蒗| 修武县| 大冶市| 西丰县| 泗水县| 兴义市| 临潭县| 达州市| 旬阳县| 郁南县| 嘉义县|